Even Better Hep C Outcome with Vertex’s Quad Combo | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Side Effects of the Two New Hep C Drugs

Back to News Homepage
Next

French Make Progress with Preventive Hep C Vaccine

Even Better Hep C Outcome with Vertex’s Quad Combo

The Editors at Hepatitis Central
August 2, 2011

Print this page

In a trial called Zenith, Vertex finds that a combination of four drugs knocked out Hepatitis C in half of participants in just 12 weeks.

Vertex 4-drug hepatitis C combo shows promise

Source: reuters // Reuters

* Treatment combines VX-222, Incivek and 2 older drugs

* Half of patients on treatment rid of virus in 12 weeks

* Vertex shares fall 0.6 percent (Adds analyst comment, safety details, background, updates shares)

CHICAGO, July 26 (Reuters) – As many as half of hepatitis C patients in a small midstage trial who received a four-drug combination, including two Vertex Pharmaceuticals medicines, were able to stop treatment after just 12 weeks, according to interim results from the study.

Vertex on Tuesday released preliminary results of the trial, which added the company’s experimental oral drug VX-222 to its recently approved Incivek pill and the traditional standard treatments of pegylated interferon and ribaviron.

Continue reading this entire article:
http://www.trust.org/item/20110726173407-3r5gj/

No Comments - be the first!
Share
Share
Previous

Side Effects of the Two New Hep C Drugs

Back to News Homepage
Next

French Make Progress with Preventive Hep C Vaccine

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.